Jean-Charles Soria logo Gustave Roussy logo

Jean-Charles Soria

General Director, Gustave Roussy (France)


Jean-Charles Soria is General Director of Gustave Roussy, the largest comprehensive cancer center in Europe, since January 2020.

Previously (2017-2019), he was Senior Vice President, Research & Development Oncology at AstraZeneca. As SVP, he led the cross-functional teams responsible for the strategy, growth, and advancement of the early oncology biologics portfolio, which includes immuno-oncology, cell therapy and antibody drug conjugates.

Among his previous experience, he is a Professor of Medicine and Medical Oncology at South-Paris University since 2006. A tenure-track and full-time cancer specialist at Institute Gustave Roussy – one of the world’s leading cancer-research institutes and the premier European Cancer Center.

As a medical oncologist and scientist, he made substantial research contributions toward potential therapeutic treatments for cancer, especially in precision medicine and immuno-oncology.

Education includes being trained as a medical oncologist and obtaining the Silver medal from Paris Medical School in 1997. Gained a PhD degree summa cum laude in the fundamental basis of oncogenesis in 2001, and completed training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he held an Adjunct Professorship in 2012.

Main research interests have been: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medicine.

Contributed to over 660 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, JCO, Annals of Oncology.

Jean-Charles Soria logo

Jean-Charles Soria

General Director, Gustave Roussy (France)


Gustave Roussy logo

Jean-Charles Soria is General Director of Gustave Roussy, the largest comprehensive cancer center in Europe, since January 2020.

Previously (2017-2019), he was Senior Vice President, Research & Development Oncology at AstraZeneca. As SVP, he led the cross-functional teams responsible for the strategy, growth, and advancement of the early oncology biologics portfolio, which includes immuno-oncology, cell therapy and antibody drug conjugates.

Among his previous experience, he is a Professor of Medicine and Medical Oncology at South-Paris University since 2006. A tenure-track and full-time cancer specialist at Institute Gustave Roussy – one of the world’s leading cancer-research institutes and the premier European Cancer Center.

As a medical oncologist and scientist, he made substantial research contributions toward potential therapeutic treatments for cancer, especially in precision medicine and immuno-oncology.

Education includes being trained as a medical oncologist and obtaining the Silver medal from Paris Medical School in 1997. Gained a PhD degree summa cum laude in the fundamental basis of oncogenesis in 2001, and completed training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he held an Adjunct Professorship in 2012.

Main research interests have been: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medicine.

Contributed to over 660 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, JCO, Annals of Oncology.


Why WIN